Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

12.28
-0.5500-4.29%
Post-market: 12.27-0.0100-0.08%16:34 EDT
Volume:287.04K
Turnover:3.55M
Market Cap:210.61M
PE:-0.98
High:12.71
Open:12.71
Low:12.22
Close:12.83
52wk High:31.55
52wk Low:9.40
Shares:17.15M
Float Shares:14.99M
Volume Ratio:0.98
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:0.95
PE(LYR):-0.84

Loading ...

Tonix Pharmaceuticals shareholders approve 2026 stock incentive plan at annual meeting

Reuters
·
May 08

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

GlobeNewswire
·
May 06

Tonix publishes TNX-4800 Lyme disease prevention presentation

Reuters
·
May 06

Tonix Pharma (TNXP) Receives a Buy from Alliance Global Partners

TIPRANKS
·
May 04

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

TIPRANKS
·
May 04

Tonix Q1 net loss widens to $40.8 million; net revenue rises to $6.9 million

Reuters
·
May 02

Tonix plans adaptive Phase 2 field trial of TNX-4800 for Lyme prevention

Reuters
·
Apr 29

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire
·
Apr 23

Tonix publishes Day 20 steady-state PK study of TONMYA in clinical journal

Reuters
·
Apr 15

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch, reports USD 208 million cash

Reuters
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Nuvalent (NUVL) and Tonix Pharma (TNXP)

TIPRANKS
·
Apr 06

Tonix CEO Seth Lederman buys TNXP shares worth $0.1 million

Reuters
·
Apr 01

Tonix publishes investor presentation highlighting TONMYA fibromyalgia drug launch progress

Reuters
·
Apr 01

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

GlobeNewswire
·
Mar 31

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Benzinga
·
Mar 30

Tonix Pharmaceuticals dosed first participant in Phase 1 TNX-1900 intranasal oxytocin study; trial measures trigeminal neurovascular reactivity in healthy female volunteers

Reuters
·
Mar 26

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of Tnx-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

THOMSON REUTERS
·
Mar 26

Tonix publishes investor presentation on TONMYA fibromyalgia launch and pipeline plans

Reuters
·
Mar 25

BRIEF-Tonix Pharmaceuticals Announces Presentations At World Vaccine Congress Washington 2026

Reuters
·
Mar 24

Tonix Pharmaceuticals Holding Corp. Announces Annual Shareholder Meeting

Reuters
·
Mar 21